Important Safety Information Patient Information Full Prescribing Information

For postmenopausal women and adult men with ER+/HER2- ESR1-mutated mBC following progression on hormone therapy.

Stemline is seeking individuals who are interested in sharing their experience with ER+/HER2- ESR1-mutated mBC and/or ORSERDU and potentially offering their perspective to others impacted by mBC.

Please fill out the form below and a representative from Stemline will be in touch with you to discuss eligibility requirements.

^*Required

By checking this box, I confirm that I am at least 18 years old.^*

I am a:

Patient living with a condition Caregiver of someone living with a condition

Confirm your condition:^*

ER+/HER2- Metastatic Breast Cancer (mBC)

First Name^*

Last Name^*

Email^*

Phone Number^*

Country^*

Are you or your loved one being treated with ORSERDU?

Yes No

I may be interested in sharing my story. I am voluntarily providing my personal information, including information about my health, to Stemline Therapeutics, Inc. and its agent, Snow Companies, for this purpose. I agree that Stemline Therapeutics or Snow Companies may contact me to discuss my interest in sharing my story. Stemline and/or Snow will not rent, sell, or otherwise distribute your information. The information you provide here will only be used for purposes of screening and to discuss your potential interest in this opportunity.

I agree

SUBMIT

Thank you for your interest in sharing your story.

We will be in touch with you soon.

There was a problem

Please check your information and try again

Return to form

Stemline will not use your information for any other purpose or share it with any third parties without your further consent. We will not sell your information. We will retain your information only as long as required to fulfill the purpose stated above or any additional purpose for which you provide consent. For information about our privacy practices and your data privacy rights, please review our Privacy Notice.

IMPORTANT SAFETY INFORMATION

ORSERDU may cause serious side effects, including:

Increased fat (lipid) levels in your blood (hypercholesterolemia and hypertriglyceridemia). Your healthcare provider will do blood tests to check your lipid levels before and during your treatment with ORSERDU

Before taking ORSERDU, tell your healthcare provider about all your medical conditions, including if you:

Have liver problems
Are pregnant or plan to become pregnant. ORSERDU can harm your unborn baby
Females who are able to become pregnant:
- Your healthcare provider may do a pregnancy test before you start treatment with ORSERDU
- You should use effective (contraception) birth control during treatment with ORSERDU and for 1 week after the last dose
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ORSERDU
Males with female partners who are able to become pregnant:
- You should use effective (contraception) birth control during treatment with ORSERDU and for 1 week after the last dose
Are breastfeeding or plan to breastfeed. It is not known if ORSERDU passes into your breast milk. Do not breastfeed during treatment with ORSERDU and for 1 week after the last dose

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ORSERDU and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

The most common side effects of ORSERDU include:

Muscle and joint (musculoskeletal) pain
Nausea
Increased cholesterol and triglyceride levels in your blood
Increased liver function tests
Tiredness
Decreased red blood cell counts
Vomiting
Decreased salt (sodium) levels in your blood
Increased kidney function test
Decreased appetite
Diarrhea
Headache
Constipation
Stomach-area (abdominal) pain
Hot flush
Indigestion or heartburn

Your healthcare provider may decrease your dose, temporarily stop, or completely stop treatment with ORSERDU, if you develop certain side effects.

ORSERDU may affect fertility in males and in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you.

ORSERDU is available as 345 mg and 86 mg tablets.

These are not all the possible side effects of ORSERDU. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

INDICATION

ORSERDU (elacestrant) is a prescription medicine to treat women who have gone through menopause and adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), and whose disease has progressed after endocrine therapy.

Your healthcare provider will perform a test to make sure that ORSERDU is right for you.

It is not known if ORSERDU is safe and effective in children.

Please see full Prescribing Information, including Patient Information.